Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment

To the Editor: We read with great interest the review series by Kreher et al1 and commend the authors for synthesizing the current available evidence regarding the risk of melanoma and non-melanoma skin cancer under a host of immunosuppressive agents commonly utilized in dermatology. While the authors pursue a thorough, evidence-based approach to discussing the risk of cutaneous malignancies with immunosuppressants, we noticed that the authors do not mention the risk of cutaneous T-cell lymphoma (CTCL) associated with dupilumab.